

**PAD INTERVENTIONAL MARKET ANALYSIS BASED ON TREATMENT
WITH ANGIOPLASTY OR ATHERECTOMY**

Table of Contents

ANALYSIS OF ICD-9 PROCEDURE DATA	5
METHODOLOGY	5
DATA SOURCE AND LIMITATIONS	6
INPATIENT INTERVENTIONAL MARKET BY TYPE OF PROCEDURE	6
2006 INPATIENT PROCEDURES EXCEEDED HALF A MILLION	6
ENDOVASCULAR GAINS SHARE FROM SURGERY 1997-2006	7
PRIMARY AMPUTATION REMAINS A HIGH PERCENTAGE OF PROCEDURES.....	9
OVERVIEW OF 2006 INPATIENT INTERVENTIONAL MARKET BY VASCULAR TERRITORY	10
REVASCULARIZATION PROCEDURES SUITABLE FOR TREATMENT WITH ANGIOPLASTY OR ATHERECTOMY.....	11
AORTOILIAC OR PELVIC DISEASE.....	11
<i>Disease Characteristics</i>	11
<i>Procedures</i>	11
ABOVE KNEE—FEMOROPOPLITEAL DISEASE	13
<i>Disease Characteristics</i>	13
<i>Procedures</i>	14
BELOW KNEE—TIBIAL AND PERONEAL DISEASE	15
<i>Disease Characteristics</i>	15
<i>Procedures</i>	16
AMPUTATION.....	18
ANALYSIS OF STENTING IN THE LOWER LIMBS.....	19
ESTIMATED OUTPATIENT ENDOVASCULAR PROCEDURES 2006.....	20
METHOD AND ASSUMPTIONS	20
INPATIENT AND OUTPATIENT ENDOVASCULAR PROCEDURES BY VASCULAR TERRITORY	20
ENDOVASCULAR PROCEDURES BY DEVICE TYPE AND TERRITORY	21
SUMMARY OF INPATIENT AND OUTPATIENT REVASCULARIZATION MARKET.....	23
ENDOVASCULAR BY TYPE OF PROCEDURE.....	23
<i>Analysis of Angioplasty and Atherectomy Procedures 2003-2006</i>	24
ENDOVASCULAR AND SURGICAL MARKET BY TYPE OF PROCEDURE	24
U.S. PAD PROJECTIONS 2000-2020	25
MARKET POTENTIAL FOR REVASCULARIZATION PROCEDURES.....	26
ASSUMPTIONS EMPLOYED TO CALCULATE MARKET POTENTIAL.....	26
ENDOVASCULAR TO GAIN SHARE OF REVASCULARIZATION MARKET	27

POTENTIAL REVASCULARIZATION PROCEDURES 2000-2020	29
U.S. PAD MARKET POTENTIAL BY TYPE OF PROCEDURE.....	29
ENDOVASCULAR MARKET PROJECTIONS BY VASCULAR TERRITORY	30
ASSUMPTIONS	30
PERCENTAGE OF PATIENTS REVASCULARIZED REMAINS CONSTANT	30
PERCENTAGE OF PATIENTS DIAGNOSED AND TREATED PROJECTED TO INCREASE.....	31
<i>Reflects Technological Innovation and Growing Knowledge and Awareness of PAD</i>	<i>31</i>
BELOW KNEE ANGIOPLASTY/ATHERECTOMY PROCEDURES TO EXPAND FASTER THAN THOSE IN OTHER VASCULAR TERRITORIES.....	32
ENDOVASCULAR PATIENTS TREATED WITH ANGIOPLASTY/ATHERECTOMY OR PRIMARY STENTS	32
FUTURE ROLE OF PRIMARY STENTING	32
AORTOILIAC PRIMARY STENTING PROJECTED TO CONTINUE SHARE GAINS	32
INFRAINGUINAL PRIMARY STENTING: TWO ALTERNATIVE SCENARIOS	32
INFRAINGUINAL PRIMARY STENTING GAINS SHARE.....	33
INFRAINGUINAL PRIMARY STENTING DECLINES	33
AORTOILIAC ENDOVASCULAR PROCEDURES 2006-2020.....	35
PRIMARY STENTING GAINS SHARE RAPIDLY	35
PRIMARY STENTING GAINS SHARE MODERATELY	36
ABOVE KNEE ENDOVASCULAR PROCEDURES 2006-2020	38
PRIMARY STENTING GAINS SHARE	38
PRIMARY STENTING LOSES SHARE	39
BELOW KNEE ENDOVASCULAR PROCEDURES 2006-2020	41
PRIMARY STENTING GAINS SHARE	41
PRIMARY STENTING LOSES SHARE	42
DOLLAR VALUE OF THE PAD ENDOVASCULAR MARKET	44
APPENDIX A	46
HEALTHCARE COST AND UTILIZATION PROJECT.....	46
APPENDIX B	47
INPATIENT ENDOVASCULAR PROCEDURE ANALYSIS INCLUDING PROVISIONAL STENTS.....	47
APPENDIX C	51
MODIFICATIONS IN KEY ASSUMPTION FOR 2006-2020 PROJECTIONS	51
REFERENCES.....	52
INDEX OF TABLES	56
INDEX OF FIGURES	58

DISCLOSURE STATEMENT	59
STOCK OWNERSHIP	59
CONTACT INFORMATION	60